OMERS ADMINISTRATION Corp Sells 80,787 Shares of Revvity, Inc. (NYSE:RVTY)

OMERS ADMINISTRATION Corp lowered its position in Revvity, Inc. (NYSE:RVTY) by 94.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,157 shares of the company’s stock after selling 80,787 shares during the quarter. OMERS ADMINISTRATION Corp’s holdings in Revvity were worth $576,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Revvity by 4.1% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,032 shares of the company’s stock worth $1,231,000 after acquiring an additional 435 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Revvity by 0.4% in the fourth quarter. Janus Henderson Group PLC now owns 6,358,952 shares of the company’s stock worth $709,725,000 after purchasing an additional 23,650 shares during the last quarter. Gotham Asset Management LLC increased its position in shares of Revvity by 37.9% in the fourth quarter. Gotham Asset Management LLC now owns 163,756 shares of the company’s stock worth $18,277,000 after purchasing an additional 45,042 shares during the last quarter. Focus Partners Wealth raised its stake in Revvity by 139.7% in the fourth quarter. Focus Partners Wealth now owns 6,217 shares of the company’s stock valued at $694,000 after purchasing an additional 3,623 shares in the last quarter. Finally, EdgePoint Investment Group Inc. lifted its position in Revvity by 51.1% during the fourth quarter. EdgePoint Investment Group Inc. now owns 4,058,231 shares of the company’s stock valued at $452,939,000 after purchasing an additional 1,372,456 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

Revvity Stock Performance

Shares of RVTY stock opened at $93.21 on Monday. The company has a market capitalization of $10.99 billion, a P/E ratio of 42.18, a PEG ratio of 3.82 and a beta of 1.02. Revvity, Inc. has a fifty-two week low of $88.53 and a fifty-two week high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a 50 day moving average price of $98.76 and a two-hundred day moving average price of $110.25.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, April 28th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.05. The company had revenue of $664.76 million during the quarter, compared to analyst estimates of $662.30 million. Revvity had a net margin of 9.81% and a return on equity of 7.68%. The firm’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.98 EPS. Analysts expect that Revvity, Inc. will post 4.94 earnings per share for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Investors of record on Friday, July 18th will be issued a dividend of $0.07 per share. The ex-dividend date is Friday, July 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. Revvity’s dividend payout ratio is presently 11.91%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on RVTY shares. The Goldman Sachs Group lowered their price objective on shares of Revvity from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 29th. KeyCorp raised their price target on Revvity from $132.00 to $145.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Raymond James reiterated an “outperform” rating and issued a $120.00 price objective (down from $145.00) on shares of Revvity in a report on Tuesday, April 29th. Wells Fargo & Company reduced their price objective on Revvity from $130.00 to $102.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Finally, Robert W. Baird dropped their target price on Revvity from $127.00 to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.64.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.